UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 57

Sortiert nach

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease

Leukemia, 2022-01, Vol.36 (1), p.288-291

2022

Link zum Volltext

Verfügbarkeit prüfen

A case of cutaneous collagenous vasculopathy associated with multiple myeloma and with a pathogenic variant of the glucocerebrosidase gene

Journal of cutaneous pathology, 2022-08, Vol.49 (8), p.717-721

2022

Link zum Volltext

Verfügbarkeit prüfen

Unicentric form of Castleman´s disease, pitfalls of diagnosis and surgical treatment

Frontiers in oncology, 2023-01, Vol.13, p.1057683-1057683

2023

Link zum Volltext

Verfügbarkeit prüfen

Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population

Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2019-09, Vol.163 (3), p.279-283

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies

Blood cancer journal (New York), 2023-09, Vol.13 (1), p.153-153, Article 153

2023

Link zum Volltext

Verfügbarkeit prüfen

P1294: REAL‐WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT‐ELIGIBLE MULTIPLE MYELOMA PATIENTS

HemaSphere, 2023-08, Vol.7 (S3), p.e0151603-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas

Biomedicines, 2022-10, Vol.10 (10), p.2535

2022

Link zum Volltext

Verfügbarkeit prüfen

P944: REAL‐WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK

HemaSphere, 2023-08, Vol.7 (S3), p.e258126d-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Severe Hyperkalemia in a Hematology-Oncology Patient

Clinical chemistry (Baltimore, Md.), 2019-02, Vol.65 (2), p.354-355

2019

Link zum Volltext

Verfügbarkeit prüfen

The impact of oral cryotherapy and oral and gastrointestinal mucositis after autologous stem cell transplantation

European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2014-04, Vol.18 (2), p.228-229

2014

Link zum Volltext

Verfügbarkeit prüfen

Determinants of refined GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies

Leukemia research, 2023-04, Vol.127, p.107052-107052, Article 107052

2023

Link zum Volltext

Verfügbarkeit prüfen

Allogeneic stem cell transplantation in patients with multiple myeloma-single center experience

Neoplasma, 2023-04, Vol.70 (2), p.294

2023

Link zum Volltext

Verfügbarkeit prüfen

Lymphocyte profile in peripheral blood of patients with multiple myeloma

Annals of hematology, 2024-06

2024

Link zum Volltext

Verfügbarkeit prüfen

The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone

Blood, 2019-11, Vol.134 (Supplement_1), p.5832-5832

2019

Link zum Volltext

Verfügbarkeit prüfen

Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data

Neoplasma, 2022-12, Vol.69 (6), p.1474

2022

Link zum Volltext

Verfügbarkeit prüfen

P-042 Early infections in myeloma patients treated with anti-BCMA bispecific antibodies

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S57-S58

2023

Link zum Volltext

Verfügbarkeit prüfen

Identification of patients at high risk of secondary extramedullary multiple myeloma development

British journal of haematology, 2022-02, Vol.196 (4), p.954-962

2022

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib‐based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data

European journal of haematology, 2021-10, Vol.107 (4), p.466-474

2021

Link zum Volltext

Verfügbarkeit prüfen

Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network

Blood, 2022-11, Vol.140 (Supplement 1), p.7200-7202

2022

Link zum Volltext

Verfügbarkeit prüfen

Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice

Blood, 2021-11, Vol.138 (Supplement 1), p.2716-2716

2021

Link zum Volltext

Verfügbarkeit prüfen

Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis

Annals of hematology, 2023-06, Vol.102 (6), p.1501-1511

2023

Link zum Volltext

Verfügbarkeit prüfen

Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission

Anticancer research, 2016-10, Vol.36 (10), p.5487-5498

2016

Link zum Volltext

Verfügbarkeit prüfen

Missense mutation in RPS7 causes Diamond-Blackfan anemia via alteration of erythrocyte metabolism, protein translation and induction of ribosomal stress

Blood cells, molecules, & diseases, 2022-11, Vol.97, p.102690-102690, Article 102690

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(55)

Publikationsform

Sprache

Englisch
(57)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease

A case of cutaneous collagenous vasculopathy associated with multiple myeloma and with a pathogenic variant of the glucocerebrosidase gene

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

Unicentric form of Castleman´s disease, pitfalls of diagnosis and surgical treatment

Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy

Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population

Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies

P1294: REAL‐WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT‐ELIGIBLE MULTIPLE MYELOMA PATIENTS

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas

P944: REAL‐WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK

Severe Hyperkalemia in a Hematology-Oncology Patient

The impact of oral cryotherapy and oral and gastrointestinal mucositis after autologous stem cell transplantation

Determinants of refined GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies

Allogeneic stem cell transplantation in patients with multiple myeloma-single center experience

Lymphocyte profile in peripheral blood of patients with multiple myeloma

The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone

Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data

P-042 Early infections in myeloma patients treated with anti-BCMA bispecific antibodies

Identification of patients at high risk of secondary extramedullary multiple myeloma development

Bortezomib‐based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data

Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network

Follow-up Analysis of Ixazomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Routine Clinical Practice

Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis

Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission

Missense mutation in RPS7 causes Diamond-Blackfan anemia via alteration of erythrocyte metabolism, protein translation and induction of ribosomal stress

Suchergebnisse filtern